Overall, current guidelines recognize liraglutide and semaglutide as first-line pharmacotherapy options for severe adolescent obesity when combined with lifestyle therapy
(download DOCX The expression and localization of GLP-1 in the TNC in the sham and NTG (9d) groups
Zhang and Kaufman 2004
Licensed from Chugai Pharmaceutical in 2018, orforglipron represents a significant advancement in the treatment of type 2 diabetes and obesity
These mechanisms explain why NMN leads the way in strategies to boost NAD+ and fight age-related decline
Stratified by GLP-1 related and non GLP-1 related treatments In the included RCTs, GLP-1 related drugs (including liraglutide, semaglutide, beinaglutide, exenatide, and AMG133) showed significant weight regain compared with control group (WMD = 1.78 kg, 95% CI 0.76 to 2.80, P = 0.006, I 2 = 85%)